Stockscreener 앱 받기
36.63
5.14%
1.79
시간 외 거래:
36.80
0.17
+0.46%
전일 마감가:
$34.84
열려 있는:
$35.02
하루 거래량:
1.32M
Relative Volume:
1.91
시가총액:
$2.84B
수익:
$688.00K
순이익/손실:
$-170.19M
주가수익비율:
-12.01
EPS:
-3.0495
순현금흐름:
$-154.68M
1주 성능:
+4.30%
1개월 성능:
+16.18%
6개월 성능:
+110.52%
1년 성능:
+61.51%
1일 변동 폭
$35.02
$37.98
1주일 범위
$32.35
$37.98
52주 변동 폭
$10.91
$37.98
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
36.63 | 2.70B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-12-17 | 개시 | Citigroup | Buy |
| 2025-09-26 | 개시 | Deutsche Bank | Buy |
| 2025-04-08 | 개시 | Leerink Partners | Outperform |
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Why Spyre Therapeutics Inc. (3920) stock appeals to dividend investors - mfd.ru
Spyre Therapeutics stock hits 52-week high at 35.82 USD - Investing.com India
Spyre Therapeutics stock hits 52-week high at 35.82 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 8.5%Should You Buy? - MarketBeat
Is Spyre Therapeutics Inc.’s ROIC above industry averageQuarterly Earnings Report & High Accuracy Buy Signal Tips - mfd.ru
Can Spyre Therapeutics Inc. lead its sector in growthNew Guidance & Free Growth Oriented Trading Recommendations - mfd.ru
How does Spyre Therapeutics Inc score in quality rankingsGDP Growth & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Spyre Therapeutics, Inc. $SYRE Shares Acquired by Candriam S.C.A. - MarketBeat
Risks Report: Is Spyre Therapeutics Inc. benefiting from interest rate changesJuly 2025 Update & Accurate Trade Setup Notifications - mfd.ru
Aug Final Week: Is Spyre Therapeutics Inc stock a hidden gemJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - baoquankhu1.vn
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week HighHere's What Happened - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Globe and Mail
Short Interest in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Drops By 13.5% - Defense World
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock - MarketBeat
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Turtle Cameron, Spyre Therapeutics CEO, sells shares worth $492k By Investing.com - Investing.com Canada
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Sees Significant Decrease in Short Interest - MarketBeat
AlphaQuest LLC Purchases 61,989 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
VIX Spike: Is SOUNW a cyclical or defensive stockJuly 2025 Macro Moves & Weekly High Potential Stock Alerts - baoquankhu1.vn
Spyre Therapeutics, Inc. (SYRE) Stock Analysis: Biotechnology Innovator with 68% Upside Potential - DirectorsTalk Interviews
Nasdaq Moves: How does Spyre Therapeutics Inc score in quality rankingsCEO Change & Smart Swing Trading Techniques - baoquankhu1.vn
Trend Review: Is Spyre Therapeutics Incs ROIC above industry averagePrice Action & Weekly Top Performers Watchlists - baoquankhu1.vn
Is Spyre Therapeutics Incs ROIC above industry averageJuly 2025 Action & High Accuracy Buy Signal Tips - baoquankhu1.vn
Spyre’s new commercial chief granted 108K stock options at $34.09 - Stock Titan
Insider Buy: Can SYFPRA maintain sales growthAnalyst Upgrade & AI Forecast Swing Trade Picks - baoquankhu1.vn
Bull Run: Can Spyre Therapeutics Inc lead its sector in growth2025 Geopolitical Influence & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Aug Final Week: Is FORL a defensive stockChart Signals & Accurate Trade Setup Notifications - baoquankhu1.vn
Big Picture: How does Spyre Therapeutics Inc score in quality rankings2025 Price Action Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
Spyre Therapeutics’ SPY002-091 Study: A Potential Game-Changer in Drug Development - MSN
Wall Street bullish on Spyre Therapeutics, Inc. (SYRE) with strong buy rating - MSN
Weekly Trades: Is FNGSs growth already priced inTrend Reversal & Growth Focused Entry Point Reports - baoquankhu1.vn
Spyre Therapeutics (SYRE) Valuation Check After Strong Recent Share Price Performance - Yahoo Finance
SYRE: BTIG Reiterates Buy Rating with $70 Price Target | SYRE St - GuruFocus
Spyre Therapeutics (NASDAQ:SYRE) Receives "Buy" Rating from BTIG Research - MarketBeat
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating - Insider Monkey
Spyre Therapeutics (NASDAQ:SYRE) Trading 7.7% HigherWhat's Next? - MarketBeat
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments By Investing.com - Investing.com Nigeria
Spyre Therapeutics Advances with Phase 1 Study of SPY002-072 - MSN
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments - Investing.com
Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership - TipRanks
Quarterly Risk: Is Spyre Therapeutics Inc a top pick in the sectorMarket Activity Summary & High Conviction Trade Alerts - baoquankhu1.vn
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts - TradingView — Track All Markets
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 - The Manila Times
Spyre Therapeutics IncSkyline Trial In UC Completes SPY001 Enrollment Ahead Of Schedule - TradingView
Six drug trials target colitis and arthritis, with first patient data in 2026 - Stock Titan
Spyre Therapeutics Appoints New CCO and Outlines 2026 Priorities - Intellectia AI
Spyre Therapeutics' CEO Sells 15,000 Shares - The Motley Fool
What technical charts say about OXYWS stockJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - moha.gov.vn
Sentiment Recap: Is Spyre Therapeutics Inc. stock cheap at current valuation2025 Pullback Review & Smart Investment Allocation Insights - Улправда
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Spyre Therapeutics Inc 주식 (SYRE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Turtle Cameron | Chief Executive Officer |
Jan 02 '26 |
Sale |
30.68 |
15,000 |
460,134 |
671,907 |
| Turtle Cameron | Chief Executive Officer |
Dec 01 '25 |
Sale |
29.02 |
15,000 |
435,356 |
686,907 |
| Turtle Cameron | Chief Executive Officer |
Nov 03 '25 |
Sale |
23.33 |
45,000 |
1,049,778 |
701,907 |
1.12%
0.87%
자본화:
|
볼륨(24시간):